A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/227
A61K 31/00 (2006.01) A61K 9/70 (2006.01) A61K 31/485 (2006.01) A61K 47/10 (2006.01) A61K 47/12 (2006.01) A61K 47/14 (2006.01)
Patent
CA 2002299
ABSTRACT OF THE DISCLOSURE Compositions for the transdermal dellvery of buprenorphine salts comprising a safe and effective amount of a pharmaceutically-acceptable buprenorphine salt in a carrier comprising: (a) a polar solvent material selected from the group consist- ing of C3-C4 diols, C3-C6 triols, and mixtures thereof; and (b) a polar lipid material selected from the group consisting of fatty acids, fatty alcohols, fatty alcohol esters, fatty acid esters, and mixtures thereof; wherein said polar solvent material and said polar lipid material are present in a weight ratio of solvent material:lipid material of from about 60:40 to about 99:1. Preferably, the polar solvent material is propylene glycol, and the polar lipid material is a C12-C18 fatty alcohol, a C12-C18 fatty acid, or an ester of a C8-C12 fatty alcohol or fatty acid. Particularly preferred polar lipid materials include oleic acid, lauryl alcohol, methyl laurate and methyl caprylate. The ratio of polar solvent material to polar lipid material is preferably from about 90:10 to about 98:2.
Drust Eugene G.
Manring Gary L.
Smith Ronald L.
Szkutak Joan B.
Drust Eugene G.
Kirby Eades Gale Baker
Manring Gary L.
Norwich Eaton Pharmaceuticals Inc.
Smith Ronald L.
LandOfFree
Compositions for the transdermal delivery of buprenorphine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the transdermal delivery of buprenorphine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the transdermal delivery of buprenorphine... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1427645